Digipath, Inc. (OTCQB: DIGP) is engaged as a cannabis testing laboratory. Shares of the cannabis testing company are gaining 13.13%, through early trading on Tuesday, November 7, 2017. Over the past month, Digipath, Inc. has seen average daily volume of 63,988 shares. However, volume of 247,212 shares or dollar volume of $44,745, has already exchanged hands on the day.
Shares of Digipath, Inc. are climbing today, after the company announced that its Chief Science Officer, Dr. Cindy Orser, will be presenting at two upcoming events regarding cannabis testing and need for standardization. The first presentation will take place on November 7, 2017, followed by next event on December 7, 2017. Here is the full press release detailing of the presentations:
Digipath, Inc. Press Release:
LAS VEGAS, Nov. 3, 2017 /PRNewswire/ — Digipath, Inc. (OTCQB: DIGP), an independent cannabis testing laboratory and media firm, is pleased to announce that its Chief Science Officer, Dr. Cindy Orser, has been invited to present on the science of cannabis at two upcoming events occurring in Nevada and California.
The first event will be at the Annual meeting of the California Association of Toxicologists entitled A House Full of Tox, being hosted by the Henderson Police Department’s and the Las Vegas Metropolitan Police Department’s forensic laboratories, and will take place Monday, November 6 and Tuesday, November 7 at the Golden Nugget hotel in Las Vegas, Nevada. From 1:30 pm to 2:30 pm on Tuesday, November 7, Dr. Orser will present on the current state of cannabis science in Nevada to enable California Toxicologists to get a snapshot of what’s to come in California with the role of a regulated cannabis industry.
The second speaking invitation came from the Genetic and Environmental Toxicology Association (GETA) of Northern California. The event is entitled, The Science of Cannabis: Endocannabinoid Signaling and Pesticides in Cannabis Cultivation, and will take place Thursday, December 7 from 1:00 pm to 5:00 pm at the Elihu M. Harris State Office Building in Oakland, California. Dr. Orser will present on the need for standardization in the cannabis industry as a prelude to the ensuing regulatory challenges ahead for the State of California under a newly regulated cannabis industry.
Dr. Cindy Orser, Chief Science Officer of Digipath, commented, “Digipath Labs is enthusiastic about participating in the scientific discussion regarding California’s burgeoning cannabis industry.”
About Digipath, Inc. Digipath, Inc. is an independent cannabis testing and media firm that supports the cannabis industry’s best practices for reliable testing and delivers cannabis news coverage and education about the cannabis industry. Digipath’s two business units are Digipath Labs and TNM News Corp. Digipath Labs™ is working to set the industry standard for testing all forms of cannabis-based products using FDA-compliant laboratory equipment and proprietary standard operating procedures (SOPs) to ensure product safety and efficacy. TNM News Corp. has pioneered a cannabis-focused news network, The National Marijuana News, which delivers news, interviews, and education on all things cannabis.
Information about Forward-Looking Statements This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.